Vildagliptin and cardiovascular risk factors – safety of therapy, drug interactions

Marcin Wełnicki; Artur Mamcarz

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

5/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

Vildagliptin and cardiovascular risk factors – safety of therapy, drug interactions

Marcin Wełnicki

,

Artur Mamcarz

Online publish date: 2018/11/30

View full text Get citation

Type 2 diabetes is a very serious problem of public health. Together with cardiovascular diseases, diabetes is responsible for most premature deaths all over the word. The latest guidelines prefer usage of antihyperglycaemic drugs with additional positive cardiovascular profile. DPP-4 inhibitors and vildagliptin among them for more than 10 years were studied also under those circumstances. In this article we will try to sum up the main studies as far as the cardiovascular safety of vildagliptin is concerned.

keywords:

Vildagliptin and cardiovascular risk factors – safety of therapy, drug interactions

Marcin Wełnicki , Artur Mamcarz

vildagliptin, type 2 diabetes, cardiovascular risk

Marcin Wełnicki

,

Artur Mamcarz